Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNP-2092 PK and Efficacy in H. pylori
NCT06190340Phase 1Completed
- Sponsor
- TenNor Therapeutics
- Start
- Nov 2016
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rifaquizinone in Helicobacter pylori infection (4 arms), sponsored by TenNor Therapeutics. Primary endpoints: Safety of TNP-2092 by Assessment of the Number of Adverse Events (AEs), Area Under the Plasma Concentration Versus Time Curve Over a Dosing Interval (AUC0-tau) on Day 1 and 11 more. Started Nov 2016; status: completed.
02
Drugs
rifaquizinone
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT06190340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06190340.